Search

Displaying results 3021 - 3030 of 10000 in total
  1. Drug

    Drotrecogin alfa

    go.drugbank.com/drugs/DB00055
    ApprovedWithdrawn

    Drotrecogin alfa was withdrawn from the market after a major study indicated that it was not effective in improving outcomes in patients with sepsis. … It is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and a light chain linked by a disulfide bond.

    Products: Xigris (5mg/vial)
  2. Drug

    Darolutamide

    go.drugbank.com/drugs/DB12941
    ApprovedInvestigational

    This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists. … [A189054,A189063] Darolutamide was developed by Bayer HealthCare Pharmaceuticals Inc. and approved by the FDA on July 30th, 2019.[L10887]

  3. Drug

    Smallpox (Vaccinia) Vaccine, Live

    go.drugbank.com/drugs/DB14711
    ApprovedInvestigational

    [L12747] In August 2024, ACAM2000 was additionally approved for the prevention of mpox infection in high-risk individuals.[L51499] … [L12747] ACAM2000, a percutaneously administered smallpox vaccine that was approved by the FDA in 2007, contains live antigens of this strain.

  4. Drug

    Corynebacterium diphtheriae

    go.drugbank.com/drugs/DB09877
    ApprovedInvestigational

    The vaccine is intramuscularly administered to provide active immunization against diphtheria in infants and children. … The bacteria culture is grown in a medium and through purification, diphtheria toxin is detoxified with formaldehyde and diafiltered.

    Mixtures: Boostrix Injektionssuspension in einer Fertigspritze, Boostrix Polio - Injektionssuspension in einer Fertigspritze
  5. Drug

    Perfluorohexyloctane

    go.drugbank.com/drugs/DB17823
    ApprovedInvestigational

    [L46491] It is an inert, slightly amphiphilic compound. … [A259741] It was approved by the FDA on May 18, 2023 for the treatment of dry eye disease.[L46536]

  6. Drug

    Erythropoietin

    go.drugbank.com/drugs/DB00016
    ApprovedInvestigational

    It works by promoting the division and differentiation of committed erythroid progenitors in the bone marrow [FDA Label]. … It has a molecular weight of approximately 30,400 daltons and is produced by mammalian cells into which the human erythropoietin gene has been introduced.

    Products: EPORATIO 20000 I E /1ML, EPORATIO 1000 I E /0.5ML
  7. Drug

    ETC-588

    go.drugbank.com/drugs/DB05456
    Experimental

    It is believed that the removal of cholesterol by ETC-588 through this pathway may result in the reversal of atherosclerosis. … ETC-588, or LUV (large unilamellar vesicles), is made of naturally occurring lipids that circulate through arteries to facilitate the role of high-density lipoprotein (HDL) in removing accumulated cholesterol

  8. Drug

    Rusfertide

    go.drugbank.com/drugs/DB17724
    ApprovedInvestigational

    [L64113] It is the first hepcidin mimetic approved for polycythemia vera.[L64113] … [L64098] The FDA approved rusfertide on August 28, 2026 for the treatment of erythrocytosis in adults with polycythemia vera, a blood cancer.

  9. Drug

    Delapril

    go.drugbank.com/drugs/DB13312
    Investigational

    Mixtures: VIVACE 30/10MG TABLETTEN, VIVACE 30/10MG TABLETTENCategories: Agents Acting on the Renin-Angiotensin System
  10. Drug

    Uridine triacetate

    go.drugbank.com/drugs/DB09144
    Approved

    It is provided in the prodrug form as uridine triacetate as this form delivers 4- to 6-fold more uridine into the systemic circulation compared to equimolar doses of uridine itself. … It can also be used as a rescue therapy if severe side effects present within 96 hours after initiation of therapy.